Ticagrelor antidote restores platelet function in phase 3 study
ACC.25 – In the phase 3 REVERSE-IT trial, the investigational monoclonal antibody bentracimab effectively and safely reversed the antiplatelet effect of ticagrelor in patients undergoing urgent surgery or with major bleeding.
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Marc Bonaca, MD
